Envisagenics

Dr. Gayatri Arun, Executive Vice President of Biology at Envisagenics, presented at A-RNA 2024 in Australia on October 23rd. Her presentation, titled "Discovery and Validation of Alternative Splicing Driven Novel Targets and Therapeutics for ALS Leveraging AI/ML," showcased Envisagenics' innovative use of artificial intelligence and machine learning to discover novel therapeutic targets for Amyotrophic Lateral Sclerosis (ALS). We were thrilled to share our cutting-edge advancements in RNA-based drug discovery and explore the potential for AI to revolutionize treatments for neurodegenerative diseases. #RNA #AIinHealthcare #ALS #AlternativeSplicing #ARNA2024 #Biotechnology #Envisagenics #Neuroscience #AI #ML

Martin Akerman, CTO and Co-Founder of Envisagenics, spoke at the AI in Drug Discovery USA conference this October, presenting "Unlocking the Potential of AI for High-Throughput Immunotherapy Drug Discovery Through RNA Splicing", hosted by SAE Media Group . His session highlighted the advanced technology behind SpliceCore and its innovative approach to identifying novel, tumor-specific, and safe epitopes for immunotherapy development. We were excited to showcase our work and are already looking forward to the next one! #AIDrugDiscovery #RNAsplicing #Immunotherapy #AIinHealthcare #Biotech #Envisagenics #SAEMediaGroup

Our Director of Business Development, Roman Braun, PhD, recently participated in a dynamic panel discussion at LabCentral Ignite’s Entrepreneur Bootcamp. The session, titled “Early Stage Partnerships with Large Pharma and Med Device Companies,” was moderated by Anton Xavier from Silicon Valley Bank. Roman shared insights on fostering partnerships and driving innovation in the life sciences sector. He was joined by Xiaodong Zhang from Novartis and David Uffer from Trinity Life Sciences. A big thank you to LabCentral for hosting such an engaging event! We’re already looking forward to the next one. #Entrepreneurship #LifeSciences #Innovation #LabCentralIgnite #Envisagenics

Maria Luisa Pineda, PhD., Co-Founder and CEO of Envisagenics, will be moderating the panel discussion "I Have a Dream": AI for Drug Discovery, hosted by EBD Group and Biotechnology Innovation Organization. She will join an esteemed group of panelists on November 5 at 4:30pm, including: Prof. Dr. Hartmut Juhl, CEO, Indivumed Therapeutics Lovisa Afzelius, General Partner, Flagship Pioneering Stephan Brock, CEO, Molecular Health Michelle Chen, Chief Business Officer, Insilico Medicine Tim James, VP - Head of In Silico R&D, Evotec Nikolaus Krall, EVP Precision Medicine, Exscientia The discussion will focus on the transformative role of AI in drug discovery, addressing key advancements, challenges, and future opportunities in the field. #AIinHealthcare #DrugDiscovery #BiotechLeadership #AIInnovation #WomenInSTEM #Envisagenics

Envisagenics has been recognized by Tracxn as one of the "Emerging Startups of Life Sciences Tech" in their latest Emerging Award Series. This recognition highlights our dedication to advancing RNA therapeutics through cutting-edge technology and underscores our growing impact within the life sciences sector. We are grateful to Tracxn for this distinction and extend our congratulations to the other innovative companies recognized in this award series. #Envisagenics #TracxnAwards #Emergingstartups #LifeSciencesTech #Techstartups #Innovation #AI #RNAtherapeutics

On National Mammography Day, Envisagenics emphasizes the vital role of early detection in breast cancer treatment. Mammograms are essential for identifying cancer at its earliest stages, enhancing treatment success. As we champion early detection, we also focus on innovative RNA-based therapies targeting molecular drivers of cancer. Prioritize your health and schedule your mammogram today. Together, we can pave the way for breakthroughs in breast cancer care. #NationalMammographyDay #BreastCancerAwareness #EarlyDetection #Envisagenics

Envisagenics' co-founder and CTO, Martin Akerman, participated in BioTechX Europe, speaking on the panel, "AI in Drug Development: From Breakthroughs to Breakdowns," on October 9th. The panel explored how artificial intelligence is transforming drug discovery and development, shedding light on the challenges and opportunities ahead in this evolving field. We were thrilled to contribute to this important discussion and are already looking forward to next year’s event! #BioTechXEurope #AIinDrugDevelopment #HealthcareInnovation #SpliceCore #Envisagenics #AI

Envisagenics co-founder and CEO, Maria Luisa Pineda, PhD., participated in the panel discussion at the Life Sciences Summit on October 8, focusing on "A C-Suite Perspective on Raising Funds and Structuring Deals in the Current Market." Maria provided invaluable insights into navigating today’s complex biotech landscape alongside other industry leaders. We are grateful for the opportunity to engage in such important conversations and look forward to implementing the strategies discussed. We’re also excited about next year’s summit and the continued collaboration within the biotech community. #LifeScienceSummit #BiotechLeadership #Fundraising #DealMaking #CSuiteLeadership #Biotech

Dr. Gayatri Arun, Executive Vice President of Biology at Envisagenics, will be presenting at A-RNA 2024 in Australia on October 23rd. Her presentation, titled "Discovery and Validation of Alternative Splicing Driven Novel Targets and Therapeutics for ALS Leveraging AI/ML," will highlight Envisagenics’ innovative approach to utilizing artificial intelligence and machine learning for the discovery of novel therapeutic targets in Amyotrophic Lateral Sclerosis (ALS). Join us as we explore cutting-edge advancements in RNA-based drug discovery and the potential for AI to revolutionize treatments for neurodegenerative diseases. #RNA #AIinHealthcare #ALS #AlternativeSplicing #ARNA2024 #Biotechnology #Envisagenics #Neuroscience #AI #ML

Envisagenics co-founder and CEO Maria Luisa Pineda, PhD. spoke at the NCI Panel: Empowering Innovation in Women’s Health on October 9, 2024, hosted by the National Cancer Institute (NCI) and the American Cancer Society. The panel featured female CEOs supported by NCI SBIR/STTR and ACS, who shared their contributions to women’s health, the role of funding in their growth, and key leadership insights. Maria shared her journey with Envisagenics and offered advice to future female entrepreneurs. Thank you for a great event—looking forward to the next one! #WomensHealth #Innovation #BiotechLeadership #FemaleEntrepreneurs #NCI #Envisagenics